Journal
GYNECOLOGIC ONCOLOGY
Volume 140, Issue 1, Pages 176-183Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2015.11.011
Keywords
Chemotherapy; Toxicity; Neuropathy
Categories
Funding
- University of Chicago Medicine Comprehensive Cancer Center (NIH) [P30 CA14599]
- NIH [RO1 CA157823]
- NIH/NIGMS [T32GM007019]
- NIH Basic Medical Research Training in Oncology training grant [5T32CA009566-28]
- NATIONAL CANCER INSTITUTE [T32CA009566, R01CA157823, P30CA014599] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007019] Funding Source: NIH RePORTER
Ask authors/readers for more resources
As there are increasing numbers of cancer survivors, more attention is being paid to the long term unwanted effects patients may experience as a result of their treatment and the impact these side effects can have on their quality of life. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common long-term toxicities from chemotherapy. In this review we will briefly review the clinical presentation, evaluation and management of chemotherapy-induced peripheral neuropathy, with a focus on CIPN related to platinum and taxane agents. We will then discuss current clinical models of peripheral neuropathy and ongoing research to better understand CIPN and develop potential treatment options. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available